Abstract
Cardiovascular disease is a major health problem all over the world. The prevalence of type 2 diabetes mellitus has been rapidly increasing, together with the risk of cardiovascular events. Patients with diabetes, and/or with insulin resistance as well, have an impaired myocardial metabolism of glucose and free fatty acids (FFA) and accelerated and diffuse atherogenesis, with involvement of coronary artery tree. Significant metabolic alterations at heart level in diabetic patients are the decreased utilization of glucose and the increase in muscular and myocardial FFA uptake and oxidation, occurring as a consequence of the mismatch between blood supply and cardiac metabolic requirements. These metabolic changes are responsible both for the increased susceptibility of the diabetic heart to myocardial ischemia and for a greater decrease of myocardial performance for a given amount of ischemia, compared to non diabetic hearts. A therapeutic approach aimed at an improvement of cardiac metabolism, through manipulations of the utilization of metabolic substrates, may improve myocardial ischemia and left ventricular function. Modulation of myocardial FFA metabolism, in addition to optimal medical therapy, should be the key target for metabolic interventions in patients with coronary artery disease and diabetes. In diabetic patients with ischemic heart disease, the effects of modulation of FFA metabolism could even give greater benefit than in nondiabetic patients.
Keywords: Diabetic Heart, Energy Metabolism, Cardiovascular disease, myocardial ischemia, CARDIOMYOPATHY
Current Pharmaceutical Design
Title: Energy Metabolism in the Normal and in the Diabetic Heart
Volume: 15 Issue: 8
Author(s): Antonio Barsotti, Alberto Giannoni, Pericle Di Napoli and Michele Emdin
Affiliation:
Keywords: Diabetic Heart, Energy Metabolism, Cardiovascular disease, myocardial ischemia, CARDIOMYOPATHY
Abstract: Cardiovascular disease is a major health problem all over the world. The prevalence of type 2 diabetes mellitus has been rapidly increasing, together with the risk of cardiovascular events. Patients with diabetes, and/or with insulin resistance as well, have an impaired myocardial metabolism of glucose and free fatty acids (FFA) and accelerated and diffuse atherogenesis, with involvement of coronary artery tree. Significant metabolic alterations at heart level in diabetic patients are the decreased utilization of glucose and the increase in muscular and myocardial FFA uptake and oxidation, occurring as a consequence of the mismatch between blood supply and cardiac metabolic requirements. These metabolic changes are responsible both for the increased susceptibility of the diabetic heart to myocardial ischemia and for a greater decrease of myocardial performance for a given amount of ischemia, compared to non diabetic hearts. A therapeutic approach aimed at an improvement of cardiac metabolism, through manipulations of the utilization of metabolic substrates, may improve myocardial ischemia and left ventricular function. Modulation of myocardial FFA metabolism, in addition to optimal medical therapy, should be the key target for metabolic interventions in patients with coronary artery disease and diabetes. In diabetic patients with ischemic heart disease, the effects of modulation of FFA metabolism could even give greater benefit than in nondiabetic patients.
Export Options
About this article
Cite this article as:
Barsotti Antonio, Giannoni Alberto, Di Napoli Pericle and Emdin Michele, Energy Metabolism in the Normal and in the Diabetic Heart, Current Pharmaceutical Design 2009; 15(8) . https://dx.doi.org/10.2174/138161209787582066
DOI https://dx.doi.org/10.2174/138161209787582066 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States
Cardiovascular & Hematological Disorders-Drug Targets The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Acute Coronary Syndromes: A Role of Immune System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nutritional Interventions and Primary Prevention of Type 2 Diabetes
Current Nutrition & Food Science Hypercholesterolemia and Endothelium Dysfunction: Role of Dietary Supplementation as Vascular Protective Agents
Current Vascular Pharmacology Failing a First Anti-TNF in RA: Does it Imply a Change in Target?
Current Rheumatology Reviews Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research The Entero-Hepatic Nuclear Receptors Integrate Cholesterol, Lipid, and Bile Acid Homeostasis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Developmental Origins of Osteoporosis
Current Genomics Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Risk Factors for Development of Heart Failure
Current Cardiology Reviews